سعر Thormoxiban 20 mg 10 f.c. tabs. 2026

Rivaroxaban 20 mg film-coated tablets, pack of 10 (Egypt).

• The most common adverse reaction (>5%) in adults was bleeding.International label, same formulation · DailyMed (NLM)

• Active pathological bleeding.International label, same formulation · DailyMed (NLM)
• Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (NLM)

• Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant if stopped for reasons other than bleeding or end of therapy.International label, same formulation · DailyMed (NLM)
• Boxed warning: epidural or spinal haematomas have occurred in patients receiving neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (NLM)
• Increases the risk of serious or fatal bleeding; concomitant aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs or SSRIs/SNRIs further increase bleeding risk.International label, same formulation · DailyMed (NLM)

• Aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs/SNRIsConcomitant use increases bleeding risk.DailyMed (NLM)

• Limited data in pregnant women are insufficient to inform drug-associated risk; use with caution because of potential pregnancy-related haemorrhage and/or emergent delivery; anticoagulant effect cannot be reliably monitored.International label, same formulation · DailyMed (NLM)
• Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (NLM)

• Rivaroxaban: Highly selective direct factor Xa inhibitor with oral bioavailability; inhibition of factor Xa interrupts the intrinsic and extrinsic coagulation pathways, inhibiting thrombin formation and thrombus development; does not inhibit thrombin and has no demonstrated effect on platelets (EU SmPC).